Sign In
Buy NPCE
$12.89
-0.86 (-6.25%)
At Close: Jul 31, 2026
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
07:03am, Monday, 08'th Jan 2024
Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
07:07am, Thursday, 21'st Dec 2023
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Tuesday, 19'th Dec 2023
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
First of its kind, multi-year collaboration leverages RNS System's data to track responses of implanted RNS System patients enrolled in a biotechnology company's clinical trial
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
08:00am, Friday, 01'st Dec 2023
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
08:00am, Tuesday, 21'st Nov 2023
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript
09:44pm, Monday, 06'th Nov 2023
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief E
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
04:03pm, Monday, 06'th Nov 2023
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
04:05pm, Tuesday, 17'th Oct 2023
- Upgraded nSight Platform Improves Clinicians' Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming' Enables Complete Programming Set Transfer Directly to RNS Tablet - - F
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
05:01pm, Monday, 16'th Oct 2023
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Wednesday, 20'th Sep 2023
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, to
NeuroPace: A Speculative Epilepsy Play
05:22am, Tuesday, 05'th Sep 2023
NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has s
NeuroPace to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 24'th Aug 2023
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21 st Annual Global Healthcare Conference - - Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif.,
NeuroPace, Inc. (NPCE) Q2 2023 Earnings Call Transcript
10:17am, Friday, 11'th Aug 2023
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Exe
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
04:05pm, Tuesday, 18'th Jul 2023
MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
